Optibrium and The Edge collaborate to integrate StarDrop with BioRails platforms
Combination provides an enterprise platform for comprehensive data management, analysis and compound design in drug discovery.
Optibrium and The Edge Software Consultancy have announced a collaboration to provide an integrated solution linking the StarDrop and BioRails platforms. The combination provides a seamless drug discovery workflow linking the latest research data directly from the lab through to decision making regarding the next round of synthesis and testing, reducing the time and cost to identify new optimisation strategies and target high quality compounds.
BioRails enables organisations to optimise the generation of high quality biological results stored in a dedicated data mart. The seamless link with StarDrop’s comprehensive capabilities for compound design, optimisation and data analysis ensures that project teams have instant access to the latest data on their compounds and can use them effectively, leading to better decisions and shorter project timelines.
The BioRails platform is designed to address a range of workflow driven research activities. BioRails can be used to design flexible processes and workflows for capturing experimental data, defining the procedures used to reliably capture high quality information. By separating design from execution BioRails provides separation between the plan and reality. This allows scientists to use the system across the full range of scientific investigations from routine activities such as ADME to more exploratory research such as in vivo behavioural studies.
Researchers can now seamlessly retrieve their biological results from BioRails using an intuitive, drag-and-drop search interface within StarDrop that enables users to easily create, share and execute database queries. StarDrop provides a highly visual way to interpret these data and their relationships with compound structures, clearly highlighting the best chemistries and multi-parameter optimisation strategies for drug discovery.
Dr Matthew Segall, CEO of Optibrium, commented: “We are delighted to be working with The Edge to provide integrated solutions to our mutual customers. We know that gaining convenient access to the latest data and using them to make good optimisation decisions is a challenge, particularly in smaller organisations without an established informatics infrastructure, and this collaboration enables us to provide a complete solution to their needs.”
“We were impressed with the design elements of Optibrium’s solutions, which rely on access to high quality results. The complimentary aspects of our solutions were clear and our experience of working together to the benefit of our customers has been very positive. We look forward to bringing this capability to many more organisations, large and small”, said Dr Andrew Lemon, The Edge’s CEO.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.